FDA Bans Oscar Bobo for Five Years Over Mislabeled Drug Imports
Published Date: 5/15/2026
Notice
Summary
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Five‑Year Drug Import Debarment
Oscar Bobo is banned for 5 years from importing or offering to import any drug into the United States, effective May 15, 2026. FDA found that between April 5, 2019 and September 3, 2024 he imported or offered for import 8 parcels containing 10 products (5,970 tablets) that were misbranded, and he waived his right to a hearing by not responding by March 25, 2026. Mr. Bobo may apply at any time for termination of the debarment under section 306(d)(1) of the FD&C Act by submitting an application as directed in the notice.
Importing for Debarred Person Is Prohibited
During Mr. Bobo's 5-year debarment, importing or offering for import any drug "by, with the assistance of, or at the direction of" Oscar Bobo is a prohibited act under section 301(cc) of the FD&C Act, effective May 15, 2026. That prohibition applies to conduct during the debarment period and may expose anyone who assists or acts at his direction to enforcement consequences.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-09766, Notice of Final Federal Agency Actions on Proposed Transportation Project in State Florida
Florida’s Department of Transportation is ready to upgrade Clearlake Road from a two-lane street to a safer, four-lane road with a cool new roundabout and bike-friendly paths on both sides. If you want to challenge these changes, you’ve got until October 13, 2026, to speak up. This project promises smoother traffic and better travel for everyone in the area!
Next: 2026-09768, Notice of Determinations; Culturally Significant Objects Being Imported for Exhibition-Determinations: “Tarot! Renaissance Roots, Modern Visions” Exhibition
The U.S. government has approved special Tarot art pieces from other countries to be shown temporarily at The Morgan Library & Museum in New York and possibly other places. This means the exhibition is officially recognized as important to culture and the nation. No costs or deadlines affect the public, but the show highlights cool Renaissance and modern Tarot art for everyone to enjoy.